Alle Studien
RekrutierungTherapeutische Bestätigung (Phase III)Interventionell

A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type

This important study is looking into a new medication called AVP-786. It's designed for people living with Alzheimer's disease who sometimes become agitated. Researchers want to find out if this medicine can help make these feelings of agitation less severe. They also want to understand if the medicine is safe and if people can take it without too many side effects. To do this, some participants will receive the actual medicine, while others will receive a placebo – a pill that looks the same but contains no active medicine. This allows researchers to compare the effects accurately. The study will measure changes in agitation over time to see how well the treatment works.

Auf einen Blick

Status
Rekrutierung
Phase
Therapeutische Bestätigung (Phase III)
Sponsor
Otsuka Pharmaceutical Development & Commercialization Inc., Otsuka Pharmaceutical Development & Commercialization Inc.
Einschreibeziel
267
Starten
14. Mai 2024

Worum geht es in dieser Studie?

This study is about helping people with Alzheimer's disease who experience agitation. Agitation can mean someone feels restless, anxious, or distressed, and it can be challenging for both the person with dementia and their carers. Researchers are testing a new medicine called AVP-786 to see if it can help reduce these feelings.

Imagine a large group of people with Alzheimer's who experience agitation. Half of them will receive the new medicine, AVP-786, and the other half will receive a 'dummy' pill, called a placebo. Neither the patients nor their doctors will know who is getting which. This is done so everyone can be sure that any changes seen are truly due to the medicine and not just other factors.

The main goal is to measure how much agitation changes in people taking the medicine compared to those taking the dummy pill. They will use special ways to score agitation levels at the beginning and again at the end of the study. They also want to see if the medicine is safe and doesn't cause too many unwanted side effects. The results from this study will help doctors decide if AVP-786 could be a helpful treatment option in the future.

Wichtige Erkenntnisse

  • This study is testing a new medicine for agitation in Alzheimer's.
  • It aims to see if AVP-786 is safe and effective.
  • Participants will get either the new medicine or a dummy pill.
  • The study helps advance understanding of Alzheimer's treatments.
  • Your participation is voluntary and you can withdraw at any time.

Wer könnte berechtigt sein?

This study is looking for both men and women aged 18 or older. Participants must have been diagnosed with Alzheimer's disease and be experiencing agitation.

There might be other specific health requirements or medications that could prevent someone from joining. These details would be discussed with you by the study doctor to make sure the study is a good fit.

It's very important that you or your loved one meet all the study's requirements to ensure everyone's safety and to make sure the study results are reliable.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Do you have a diagnosis of Alzheimer's disease?
  3. Are you currently experiencing agitation?
  4. Können Sie regelmäßig an Studienbesuchen teilnehmen?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, you would receive either the new study medication, AVP-786, or a placebo (a dummy pill). The study involves regular visits to the clinic where doctors and nurses will check your health, ask questions about your agitation levels, and monitor any side effects. You'll likely have physical exams and potentially some blood tests. The medication would need to be taken as directed. The study would last for a specific period, and after you stop taking the study medication, there might be follow-up visits to ensure your well-being. The total length of your involvement will be clearly explained by the study team.

Potenzielle Risiken und Vorteile

Taking part in any medical study has potential benefits and risks. A potential benefit of this study is that the new medicine might help reduce agitation. You would also be contributing to medical research that could help many others in the future. However, there's no guarantee the medicine will work, and you might experience side effects, just like with any medication. You are free to leave the study at any time, for any reason, without it affecting your medical care.

Standorte (7)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Griechenland
  • —
    Unbestätigt
    Estland
  • —
    Unbestätigt
    Bulgarien
  • —
    Unbestätigt
    Polen
  • —
    Unbestätigt
    Portugal
  • —
    Unbestätigt
    Dänemark
  • —
    Unbestätigt
    Deutschland

Häufige Fragen

What is agitation?

Agitation in Alzheimer's disease can mean feeling restless, anxious, irritable, or distressed. It's often expressed through actions like pacing, fiddling, or shouting.

Was ist ein Placebo?

A placebo is a 'dummy' pill or treatment that looks exactly like the real medicine but doesn't contain any active drug. It helps researchers compare the effects of the new medicine accurately.

What is AVP-786?

AVP-786 is the name of the new medicine being tested in this study. It's a combination of two ingredients: deudextromethorphan hydrobromide and quinidine sulfate, which work together.

Werde ich wissen, ob ich das Medikament oder das Placebo erhalte?

No, neither you nor your study doctor will know whether you are receiving the real medicine or the placebo. This is called 'double-blind' and is a standard way to get fair results.

Wie lange wird die Studie dauern?

The total length of the study for an individual will be explained by the research team. It usually involves a period of taking the medication and some follow-up visits.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Phase 3, multicenter, randomized, double-blind, placebo-co… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.